Chromocell Therapeutics Corporation (CHRO) Stock
CHRO is no longer traded. Chromocell Therapeutics was delisted from the NYSE American in September 2025.
Prices on this page are historical; the last trade was September 2, 2025 at $22.46.
Chromocell Therapeutics stock price history
CHRO final trading statistics
- Final close
- $22.46
- Final trading day
- Sep 2, 2025
- Market cap at delisting
- $8.90M
- Shares outstanding
- 6.60M
- Final 52-week range
- $0.45 – $54.29
- Avg. volume (final 3 mo.)
- 62,269
- All-time high (split-adj.)
- $48.00 · Feb 2024
- All-time low (split-adj.)
- $5.41 · Nov 2024
- Return since IPO
- -53.2%
- Beta
- —
- Book value / share
- -$6.79
- Price / book
- -3.31
Chromocell Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $0.00 | -$8.0M | — |
| FY2023 | $0.00 | -$7.4M | — |
| FY2023 | $0.00 | -$7.4M | — |
| FY2022 | $0.00 | -$2.5M | — |
| FY2022 | $0.00 | -$2.5M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Chromocell Therapeutics Corporation
Channel Therapeutics Corporation, a clinical-stage biotech company, develops and commercializes new therapeutics to alleviate pain. It targets sodium ion-channel NaV1.7; and develops NaV blockers that target the body's peripheral nervous system. The company's lead compound is CC8464, which has completed Phase 1 clinical trials for the treatment of moderate-to-severe pain in erythromelalgia and idiopathic small fiber neuropathy. It also develops CT2000 as a topical agent for the treatment of both acute and chronic eye pain; and CT3000 to treat post operative pain with the use of nerve blocks. The company was Chromocell Therapeutics Corporation and changed its name to Channel Therapeutics Corporation in November 2024. Channel Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
Chromocell Therapeutics stock FAQ
What happened to Chromocell Therapeutics stock?
Chromocell Therapeutics stock was delisted from the NYSE American. Its final close was $22.46 on September 2, 2025.
Is CHRO stock still trading?
No. CHRO was delisted from the NYSE American in September 2025 and no longer trades on a U.S. exchange.
What was the last price of CHRO stock?
CHRO closed at $22.46 on its final trading day, September 2, 2025, for a market value of about $8.90M.
What were Chromocell Therapeutics's revenue and earnings in its last full fiscal year?
Chromocell Therapeutics reported revenue of $0.00 and net income of -$8.0M in fiscal 2024, its last full year as a public company.
When did Chromocell Therapeutics go public?
Chromocell Therapeutics Corporation stock began trading on February 16, 2024.